Akums Drugs and Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,167	1,024	+13.9%
EBITDA	175	129	+35.4%
EBITDA margin	15.0%	12.6%	+2.4 pts
Profit before tax	139	95.6	+45.6%
Net profit	101	64.7	+56.1%
EPS	₹6.53	₹4.15	+57.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024

Expenses
	1,167	1,158	1,160	1,018	1,024	1,056	1,010	1,033	1,019
	30.4	35.3	34.3	32.4	26.7	17.5	14.6	13.5	6.5
	1,197	1,193	1,194	1,050	1,051	1,073	1,025	1,047	1,026
	682	587	611	553	548	624	565	506	559
	26.5	62.9	60.3	56.7	21.1	19.5	30.3	90.9	40.9
	−63.2	10.6	7.0	−16.8	12.9	−4.2	7.5	−0.6	−4.3
	201	199	189	189	176	184	176	180	176
	24.8	23.9	23.7	23.3	23.1	4.5	5.1	11.9	13.0
	41.1	40.1	39.6	37.9	36.9	40.0	44.5	34.9	34.1
	145	147	145	141	137	139	111	136	119
	1,058	1,070	1,076	984	955	1,006	939	959	938
	175	152	147	94.5	129	93.9	121	121	128
	134	112	107	56.6	92.1	53.9	76.8	86.3	94.0
Profit
	139	123	118	65.7	95.6	66.9	86.3	87.9	87.5
	0.0	−1.8	−18.2	0.0	0.0	8.2	4.8	3.7	0.0
	139	121	99.6	65.7	95.6	75.1	91.1	91.6	87.5
	27.2	19.3	27.0	19.1	24.4	18.2	18.7	24.1	18.8
	11.1	20.6	4.9	3.8	6.5	−92.7	6.0	0.9	7.5
	38.3	39.9	31.9	23.0	31.0	−74.5	24.7	24.9	26.3
	101	81.3	67.7	42.7	64.7	150	66.3	66.7	61.2
	101	81.3	67.7	42.7	64.7	150	66.3	66.7	61.2
	3.1	2.8	0.7	−4.3	1.7	−1.0	0.2	−0.9	0.6
	104	84.1	68.4	38.4	66.4	149	66.5	65.8	61.8
	100	84.6	66.3	40.8	63.5	148	65.2	65.2	60.2
	1.0	−3.3	1.4	1.9	1.2	2.0	1.1	1.4	1.0
Per share
	₹6.53	₹5.53	₹4.33	₹2.66	₹4.15	₹9.64	₹4.26	₹4.37	₹4.21
	₹6.53	₹5.53	₹4.33	₹2.66	₹4.15	₹9.64	₹4.26	₹4.37	₹4.21
Other comprehensive income — detail
	3.1	2.8	0.7	−4.3	1.7	−1.0	—	—	—
	3.9	3.6	0.7	—	—	−1.3	0.2	−1.2	0.8
	0.8	0.9	0.0	5.4	−2.3	−0.2	—	—	—
	—	—	—	—	—	—	0.1	−0.3	0.2
	0.0	−0.0	—	—	—	—	—	—	—
	0.0	0.0	0.0	−1.1	0.6	0.0	—	—	—
	103	87.4	67.0	36.5	65.2	147	65.4	64.3	60.8
	1.0	−3.3	1.4	1.9	1.2	2.0	1.1	1.5	1.0
Per share — as-filed variants
	₹6.53	₹5.53	₹4.33	₹2.66	₹4.15	₹9.64	₹4.26	₹4.37	₹4.21
	₹6.53	₹5.53	₹4.33	₹2.66	₹4.15	₹9.64	₹4.26	₹4.37	₹4.21
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	521	497	481	425	442	416	408	437	423
	44.7%	43.0%	41.5%	41.8%	43.2%	39.5%	40.4%	42.3%	41.5%
Adjusted (ex-exceptional items) — derived
	139	123	118	65.7	95.6	66.9	86.3	87.9	87.5
	0.0	−1.8	−18.2	0.0	0.0	8.2	4.8	3.7	0.0
	101	82.5	80.1	42.7	64.7	141	62.8	64.0	61.2
	₹6.53	₹5.61	₹5.12	₹2.66	₹4.15	₹9.11	₹4.04	₹4.19	₹4.21

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersALIVUS AGARWALEYE ADVENZYMES APLLTD AARTIPHARM AARTIDRUGS CORONA HCGMcap ₹11,346 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,019.1	1,033.1	1,010.4	1,055.5	1,024.0	1,017.5	1,159.6	1,157.9	1,166.6
Other Income	6.5	13.5	14.6	17.5	26.7	32.4	34.3	35.3	30.4
Total Income	1,025.7	1,046.6	1,025.0	1,073.1	1,050.8	1,049.9	1,193.9	1,193.2	1,197.0
Expenses
+ Cost of Materials Consumed	559.5	505.7	564.6	623.8	547.9	552.6	611.3	586.9	682.1
+ Purchases of Stock-in-Trade	40.9	90.9	30.3	19.5	21.1	56.7	60.3	62.9	26.5
+ Changes in Inventories	-4.3	-0.6	7.5	-4.2	12.9	-16.8	7.0	10.6	-63.2
+ Employee Benefit Expense	176.2	180.1	175.6	183.9	176.1	189.3	189.4	199.0	201.4
+ Finance Costs	13.0	11.9	5.1	4.5	23.1	23.3	23.7	23.9	24.8
+ Depreciation & Amortisation	34.1	34.9	44.5	40.0	36.9	37.9	39.6	40.1	41.1
+ Other Expenses	118.9	135.8	111.1	138.7	137.0	141.2	144.8	146.7	145.1
Total Expenses	938.2	958.7	938.7	1,006.2	955.1	984.2	1,076.1	1,070.2	1,057.8
EBITDA	128.0	121.2	121.4	93.9	129.0	94.5	146.9	151.7	174.7
EBIT	94.0	86.3	76.8	53.9	92.1	56.6	107.2	111.6	133.6
Profit
PBT before Exceptional Items	87.5	87.9	86.3	66.9	95.6	65.7	117.8	123.0	139.2
+ Exceptional Items	0.0	3.7	4.8	8.2	0.0	0.0	-18.2	-1.8	0.0
Pretax Income	87.5	91.6	91.1	75.1	95.6	65.7	99.6	121.2	139.2
+ Current Tax	18.8	24.1	18.7	18.2	24.4	19.1	27.0	19.3	27.2
+ Deferred Tax	7.5	0.9	6.0	-92.7	6.5	3.8	4.9	20.6	11.1
Tax Expense	26.3	24.9	24.7	-74.5	31.0	23.0	31.9	39.9	38.3
Net Income	61.2	66.7	66.3	149.6	64.7	42.7	67.7	81.3	101.0
+ Net Income — Continuing Ops	61.2	66.7	66.3	149.6	64.7	42.7	67.7	81.3	101.0
+ Other Comprehensive Income	0.6	-0.9	0.2	-1.0	1.7	-4.3	0.7	2.8	3.1
Total Comprehensive Income	61.8	65.8	66.5	148.6	66.4	38.4	68.4	84.1	104.1
Net Income to Common	60.2	65.2	65.2	147.6	63.5	40.8	66.3	84.6	100.0
Minority Interest	1.0	1.4	1.1	2.0	1.2	1.9	1.4	-3.3	1.0
Per Share
Basic EPS	4.21	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Diluted EPS	4.21	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	-1.0	1.7	-4.3	0.7	2.8	3.1
+ Items NOT to be Reclassified to P&L	0.8	-1.2	0.2	-1.3	—	—	0.7	3.6	3.9
+ Tax on Items NOT to be Reclassified	—	—	—	-0.2	-2.3	5.4	0.0	0.9	0.8
+ Tax on Items NOT to be Reclassified — alt tag	0.2	-0.3	0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	-0.0	0.0
+ Tax on Items to be Reclassified	—	—	—	0.0	0.6	-1.1	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	60.8	64.3	65.4	146.6	65.2	36.5	67.0	87.4	103.1
Comprehensive Income — Non-controlling Interests	1.0	1.5	1.1	2.0	1.2	1.9	1.4	-3.3	1.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	4.21	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Diluted EPS — Continuing Operations	4.21	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	423.1	437.1	408.0	416.5	442.1	425.0	481.0	497.4	521.2
Gross Margin %	41.52	42.31	40.38	39.45	43.17	41.76	41.48	42.96	44.68
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	87.5	87.9	86.3	66.9	95.6	65.7	117.8	123.0	139.2
− Exceptional Items (reconciliation)	0.0	3.7	4.8	8.2	0.0	0.0	-18.2	-1.8	0.0
Net Income Adj (tax-effected)	61.2	64.0	62.8	141.4	64.7	42.7	80.1	82.5	101.0
EPS Adj	4.21	4.19	4.04	9.11	4.15	2.66	5.12	5.61	6.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	—	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	28.6	30.6	30.6	30.6	30.6	30.6	30.6	30.6	30.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Akums Drugs and Pharmaceuticals Q2 FY27 results date

Akums Drugs and Pharmaceuticals (NSE: AKUMS) will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹100 crore, up 57.6% from ₹63.5 crore in Q1 FY26 and up 18.2% from ₹84.6 crore in Q4 FY26. Revenue from operations was ₹1,167 crore, up 13.9% year on year and up 0.8% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 8 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 2 November 2026Monday · notice filed 28 Oct
Q1 FY27 net profit: ₹100 Cr+57.6% vs Q1 FY26+18.2% vs Q4 FY26
Q1 FY27 revenue: ₹1,167 Cr+13.9% vs Q1 FY26+0.8% vs Q4 FY26
Q1 FY27 operating margin: 11.5%+2.5 pts vs Q1 FY26+1.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹40.8 CrRevenue ₹1,018 Cr
Q1 FY27 EPS (basic): ₹6.53

Questions

When will Akums Drugs and Pharmaceuticals announce its Q2 FY27 results?

On 2 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 13 November 2025.

What will Akums Drugs and Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹40.8 crore and revenue from operations ₹1,018 crore. The latest quarter, Q1 FY27, had a net profit of ₹100 crore and revenue of ₹1,167 crore.

What were Akums Drugs and Pharmaceuticals' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹100 crore, up 57.6% from ₹63.5 crore in Q1 FY26 and up 18.2% from ₹84.6 crore in Q4 FY26. Revenue from operations was ₹1,167 crore, up 13.9% year on year and up 0.8% from the previous quarter.

How has Akums Drugs and Pharmaceuticals' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹40.8 crore in Q2 FY26, ₹66.3 crore in Q3 FY26, ₹84.6 crore in Q4 FY26 and ₹100 crore in Q1 FY27. That is ₹292 crore over the four quarters, down 14.6% from ₹341 crore in the four quarters before. Revenue from operations: ₹1,018 crore, ₹1,160 crore, ₹1,158 crore and ₹1,167 crore.

What was Akums Drugs and Pharmaceuticals' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹255 crore in FY26 (April 2025–March 2026), down 24.5% from ₹338 crore in FY25.

What was Akums Drugs and Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹4,359 crore in FY26 (April 2025–March 2026), up 5.8% from ₹4,118 crore in FY25.

Where do these Akums Drugs and Pharmaceuticals figures come from?

From Akums Drugs and Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.